Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
复制标题
DOI：
10.1158/2326-6066.cir-14-0039
复制
发表时间：
2014-05-01
影响因子：
10.1
通讯作者：
Anderson, Ana C.
中科院分区：
文献类型：
--
作者：
Anderson, Ana C.
在过去的几年里，癌症免疫治疗领域呈指数级增长，主要是由于免疫检查点阻断的成功。靶向免疫检查点分子CTLA-4和PD-1的治疗已经在黑色素瘤、肾癌和肺癌中实现了客观缓解;然而，大量患者仍然患有这些癌症，无法从这些治疗中获益。此外，几种癌症已被证明在很大程度上对靶向CTLA-4和PD-1的疗法是难治的。这激发了人们对靶向新型免疫检查点受体的兴趣，目的是实现检查点阻断治疗癌症的全部潜力。在这方面，免疫检查点受体Tim-3表现出几个独特的功能，使其成为下一波靶向癌症免疫检查点的治疗方法的有趣候选者。(C)2014年AACR。
The cancer immunotherapy field has grown exponentially in the past few years, largely driven by the success of immune checkpoint blockade. Therapies targeting the immune checkpoint molecules CTLA-4 and PD-1 have achieved objective responses in melanoma, renal cancer, and lung cancer; however, a large number of patients are still suffering with these cancers that are not benefiting from these therapies. Moreover, several cancers have proved to be largely refractory to therapies that target CTLA-4 and PD-1. This has catalyzed interest in targeting novel immune checkpoint receptors with the goal of realizing the full potential of checkpoint blockade for treating cancer. In this regard, the immune checkpoint receptor Tim-3 exhibits several unique features that make it an intriguing candidate for the next wave of therapies that target immune checkpoints in cancer. (C) 2014 AACR.